Physician profile
Daniel John Balog
NPI 1710036470
$3,960.01
in general payments reported to CMS, 2019-2025
23 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $85.92 · 2021: $42.85 · 2022: $298 · 2023: $1,000 · 2024: $674 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.24 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $465.99 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $421.89 | 2019-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $381.17 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $344.68 | 2023-2025 | Loreev Xr |
| Allergan, INC. | $219.47 | 2019-2020 | |
| Alkermes, INC. | $213.49 | 2019-2023 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.85 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $191.98 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $159.77 | 2023-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $138.09 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $104.14 | 2019-2020 | |
| Corium, LLC | $81.00 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $80.37 | 2023-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $67.58 | 2022-2025 | Quviviq, Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63.39 | 2023-2024 | Trintellix |
| Collegium Pharmaceutical, INC. | $48.68 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $29.85 | 2019 | |
| Lundbeck LLC | $29.78 | 2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $22.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.56 | 2024 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $14.40 | 2024 | |
| Owp Pharmaceuticals, INC. | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Balog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.